Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00595907|
Recruitment Status : Completed
First Posted : January 16, 2008
Last Update Posted : January 16, 2008
|Condition or disease|
Patients either treated for active culture proven tuberculosis (TB) or having completed treatment during the preceding 6 months were recruited. Exclusion criteria were : HIV infection and previous TB. Interferon gamma release assay (T-SPOT.TB, Oxford Immunotec) was sampled during the 2 first weeks of treatment, at the end of treatment and 6 months later.
T-SPOT.TB was analysed qualitatively (pos/neg) and quantitatively (Spot forming units: SFU) to determine if there was a higher rate of negative tests at the end of treatment and 6 months after treatment than initially. Paired samples were analysed to compare SFU counts between beginning of treatment and end of treatment, and SFU counts between end of treatment and 6 months later.
Clinical response to treatment was recorded, as well as treatment failures and relapses.
|Study Type :||Observational|
|Actual Enrollment :||89 participants|
|Official Title:||Observational Study of Production of IFN-Gamma by Peripheral Lymphocytes in Response to Specific Antigens Before and After Treatment for Tuberculosis|
|Study Start Date :||October 2004|
|Actual Primary Completion Date :||July 2006|
|Actual Study Completion Date :||July 2006|
- Interferon gamma response to M. tuberculosis antigens by peripheral lymphocytes after treatment for tuberculosis [ Time Frame: 12-18 months ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00595907
|Centre antituberculeux; Geneva University Hospital|
|Geneva, Geneva 14, Switzerland, 1211|
|Principal Investigator:||Jean-Paul Janssens, M.D.||Geneva University Hospital|